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Background: Hemodialysis (HD) patients with functional iron deﬁciency often
develop resistance to recombinant human erythropoietin (rhEPO). Recent studies
have shown that intravenous ascorbic acid (IVAA) administration could override
rhEPO resistance in HD patients. This study was undertaken to test the effects of
IVAA in HD patients with normoferritinemic functional iron deﬁciency accompa-
nied by EPO-hyporesponsive anemia.
Methods: Fifty-eight HD patients with normoferritinemic anemia (between 100
and 500 mg/L) were included and divided into the control (N¼25) and IVAA
(N¼33) groups. IVAA patients received 500 mg of IVAA with each dialysis session
for 3 months and an additional 4-month follow-up after the end of the therapy.
Results: Twenty patients had a response to IVAA with a signiﬁcant increase in
hemoglobin level (Hgb41.0 g/dL) and reduction of weekly rhEPO dosage com-
pared with the control group after 3 months of treatment (Po0.05). Compared
with non-responders, transferrin saturation (TSAT) was signiﬁcantly decreased in
the responders group (26711 vs. 35714%, Po0.05) on baseline data. There was a
signiﬁcant increase in serum iron and TSAT (baseline vs. 3 months, serum iron
57722 vs. 108722 mg/dL, TSAT 26711 vs. 5277%, Po0.05) and a decrease in
serum ferritin (3777146 vs. 2337145 ng/mL, Po0.05) in the responders group
(N¼20), but no signiﬁcant changes in the control and non-responders groups
(N¼13) at 3-month treatment.
Conclusion: IVAA can be a potent and effective adjuvant therapy for HD patients
with rhEPO-resistant normoferritinemic anemia. In addition, IVAA can reduce the
dosage of rhEPO for anemia correction.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
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Anemia is one of the most important complications in
chronic kidney disease (CKD) [1]. The pathogenesis of anemia
in chronic kidney disease is multifactorial. The most impor-
tant factor is inadequate production of erythropoietin (EPO),
which is accompanied by a decline in renal function.ublished by Elsevier. This is an open access article under the CC BY-NC-
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used in the treatment of CKD-associated anemia [2,3]. Despite
the treatments with rhEPO or other erythropoiesis-stimulat-
ing agents (ESA), other factors affect the CKD-associated
anemia, such as shortened erythrocyte survival, blood loss,
iron and other nutritional deﬁciencies, hemolysis, the pre-
sence of uremic inhibitors of erythropoiesis, and inadequate
iron stores [4].
Many patients with CKD have borderline iron deﬁ-
ciency, which may be the cause of resistance to EPO
therapy [5]. Some patients with excessive iron stores
may also exhibit CKD-associated anemia and are consid-
ered to have a functional iron deﬁciency state. Functional
iron deﬁciency implies the state in which insufﬁcient iron
is released from the bone marrow. Functional iron deﬁ-
ciency cause insufﬁcient erythropoiesis [6]. Failure of bone
marrow erythropoiesis results in failure of iron utilization,
characterized by high serum ferritin concentration, and
low transferrin saturation (TSAT).
The potential role of adjuvant therapies in enhancing the
efﬁcacy of rhEPO in patients receiving maintenance dialysis
has commanded attention in recent years [7–9]. Adjuvant
therapies may help to reduce rhEPO requirements or allow
dialysis patients to achieve increased hemoglobin (Hgb)
concentrations, and derive more cost-effectiveness and
greater clinical beneﬁts from rhEPO treatment [8–10]. Cur-
rently, many studies imply that intravenous ascorbic acid
(IVAA) treatment in hemodialysis (HD) patients improved
Hgb and iron availability in EPO-hyporesponsive HD patients
with iron overload. Vitamin C acts as an antioxidant, helps
release iron from ferritin and mobilizes iron from the reticu-
loendothelial system to transferring [11]. Such effects of
vitamin C help mobilize iron from tissue storage and increase
iron utilization in erythropoiesis [12].
The purpose of the current study was to compare the
efﬁcacy of IVAA on improving anemia in EPO-hyporespon-
sive HD patients with normoferritinemia.Methods
Participants were recruited from the dialysis center of
Chosun University Hospital. The inclusion criteria were asTable 1. Baseline Characteristics
Characteristics Control group IVA
Number of patients 25
Sex (male/female) 12/13 1
Age (years) 56.9714.6 54.
Duration of hemodialysis (years) 3.973.4 5.
Causes of end-stage renal disease
Diabetes mellitus 12 (48%) 14
Chronic glomerulonephritis 5 (20%) 5
Hypertension 5 (20%) 5
Polycystic kidney disease 1 (4%) 5
Obstruction 1 (4%) 2
Unknown 1 (4%) 2
Clinical ﬁnding
Dry weight (kg) 60711 5
Ultraﬁltration amount (L) 3.170.8 3.
rhEPO dose (IU/kg/week) 152738 14
Values are expressed as frequency (%) or mean7standard deviation. IVAA,follows: age older than 19 years, HD durationZ6 months,
duration of rhEPO Z6 months, and 6 consecutive months
of stable ferritin, hematocrit, and rhEPO dose levels. All HD
patients were selected based on the inclusion criteria:
Hgbo11 g/dL, hematocrit less than 33%, and serum ferri-
tin 100–500 mg/L.
The exclusion criteria were as follows: previously diag-
nosed nonrenal cause of anemia other than iron deﬁciency;
evidence of active or occult bleeding; blood transfusion
during examination; history of malignancy, end-stage liver
disease, or chronic hypoxia; and recent infection requiring
antibiotics during examinations.
The prescription of HD was with polysulfone mem-
branes and an average blood ﬂow rate of 200–300 mL/min.
Kt/V was kept at 1.6470.18 during each treatment period.
Patients received standard care and IVAA with each HD
session. Five hundred mg of ascorbic acid mixed in 50 mL
of 5% dextrose was infused intravenously for 30 min when
each session was ended. rhEPO (Recormon, Seoul, Korea)
was administered intravenously three times per week, and
rhEPO dose was determined every month throughout the
study according to the Kidney Disease Outcomes Quality
Initiative guidelines. Maintenance iron replacement of
100 mg as ferric oral iron (Feroba, Seoul, Korea) was
administrated twice daily to all patients.
Informed consent was obtained from each patient before
sample collection. Each patient’s blood was collected before
dialysis. Blood samples for measurement of Hgb, hematocrit,
iron metabolism indices (serum iron, total iron binding
capacity [TIBC], TSAT ratio (calculated by iron/TIBC100),
serum ferritin), calcium, phosphorus, intact parathyroid hor-
mone, and spKt/V were obtained at baseline, every month
during the intervention period, and at 4 months after IVAA
intervention. The C-reactive protein (CRP), aluminum, vitamin
B12, folic acid, and vitamin C were measured at baseline, at
7 months. Responder of IVAA treatment was deﬁned as an
increase in Hgb of 1.0 g/dL at 3 months.
Statistical analysis was performed using SPSS version
12.0 statistical package (SPSS Inc., Chicago, IL, USA). The
values were expressed as mean7standard deviation. An
independent t test was used to compare the results
between groups at baseline. Analysis of variance andA group IVAA responders IVAA non-responders
33 20 13
5/18 9/11 6/7
5712.1 53.7712.8 54.9711.3
174.3 5.474.7 4.673.6
(43%) 9 (45%) 5 (39%)
(15%) 3 (15%) 2 (15%)
(15%) 3 (15%) 2 (15%)
(15%) 3 (15%) 2 (15%)
(6%) 1 (5%) 1 (8%)
(6%) 1 (5%) 1 (8%)
9713 59714 58712
370.9 3.270.9 3.570.8
4737 143734 145742
intravenous ascorbic acid; rhEPO, recombinant human erythropoietin.
Table 2. Baseline Laboratory Data of Control and Intravenous Ascorbic Acid Treated Patients
Control (N¼25) IVAA group (N¼33) IVAA responders (N¼20) IVAA non-responders (N¼13)
Hemoglobin (g/dL) 9.470.9 9.571.1 9.371.4 9.870.4
Hematocrit (%) 28.272.8 27.573.0 27.273.7 28.271.5
WBC (103/mL) 589271560 594271951 626972298 544071389
Platelet (103/mL) 204778 193754 200754 181757
Serum iron (mg/dL) 81725 65725 57722 77722
TIBC (mg/dL) 248766 227745 225752 229738
Transferrin saturation (%) 33710 30713 26711n 35714
Serum ferritin (ng/mL) 3577105 3747129 3777146 3697103
Transferrin (g/L) 1.670.3 1.770.3 1.770.3 1.770.3
Total calcium (mg/dL) 8.570.7 9.471.0 9.270.6 9.871.3
Phosphorus (mg/dL) 4.271.1 4.971.3 5.271.2 4.871.4
Intact PTH (pg/mL) 2617219 3127443 3497517 2557350
Cholesterol (mg/dL) 149739 142733 134722 153746
Serum albumin (g/dL) 4.370.3 4.170.2 4.170.2 4.070.2
Predialysis BUN (mg/dL) 71714 76717 81717 69713
Urea reduction rate (%) 75.575.9 74.975.5 73.875.4 76.775.6
spKt/V 1.770.3 1.770.3 1.770.3 1.770.3
nPCR (g/kg/day) 1.370.3 1.370.3 1.370.3 1.370.3
C-reactive protein (mg/dL) 0.871.1 0.570.4 0.470.2 0.670.7
n Po0.05 vs. control and non-responders.
Values are expressed as mean7standard deviation. BUN, blood urea nitrogen; IVAA, intravenous ascorbic acid; nPCR, normalized protein catabolic
rate; TIBC, total iron binding capacity. spKt/V reﬂects the dialysis single-pool kinetics. K is the dialyzer ultraﬁltration coefﬁcient, t is the time, and V
is the volume.
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within-group comparison for pretreatment and posttreat-
ment. The criterion for statistical signiﬁcance was Po0.05.Figure 1. Intravenous ascorbic acid (IVAA) treatment. Changes of
hemoglobin concentration (a) and weekly recombinant erythropoietin
(rhEPO) doses (b) after IVAA treatment during 3 months (mo) and
posttreatment follow-up (F/U) at 4 months. Symbols: K&, controls;
’’, responders; m non-responders. *Po0.05 vs. baselines; yPo0.05
vs. controls; #Po0.05 vs. responders.Results
Baseline clinical and laboratory data
A total of 58 patients were divided into a control group
(25 patients) and IVAA group (33 patients). Both groups
were similar in clinical data, sex, age, duration of HD,
causes of end-stage renal disease, dry weight, ultraﬁltra-
tion amount, and rhEPO dose at baseline (Table 1).
TSAT was signiﬁcantly lower in the IVAA responders
group than in the control and IVAA non-responders group
(Po0.05). Baseline CRP levels tended to be lower in the IVAA
responders group than the control and non-responders
groups, but there was no statistical difference. Hgb, hema-
tocrit, serum iron, TIBC, ferritin level, and the other factors
showed no difference among the three groups (Table 2).
Effect of IVAA treatment
Hgb was signiﬁcantly increased at 3 months and 7 months
in the IVAA responders group compared with the control and
IVAA non-responders groups (Po0.05, Fig. 1A). In the IVAA
responders group, Hgb was increased from 9.371.4 g/dL at
baseline to 11.271.7 g/dL at 3 months and maintained at
10.371.5 g/dL at 7 months. However, the control group
(9.471.9 g/dL at baseline vs. 9.670.9 g/dL at 3 months vs.
9.770.9 g/dL at 7 months) and the IVAA non-responders
group (9.870.4 g/dL vs. 9.870.5 g/dL vs. 9.870.4 g/dL)
showed no improvement in Hgb levels.
Weekly requirement of rhEPO was signiﬁcantly reduced at
3 months (89716 IU/kg/week) and 7 months (88719 IU/kg/
week) compared with baseline values (143736 U/kg/week)
Figure 2. Effects of intravenous ascorbic acid and posttreatment follow-up. Serum iron (a), TIBC (b), transferrin saturation (c) and serum ferritin
(d). Symbols: K, controls; ’, responders; m non-responders. *Po0.01 vs. baselines; yPo0.01 vs. responders; **Po0.01 vs. at 3 months.
Figure 3. Correlation between serum vitamin C level and weekly
recombinant erythropoietin (rhEPO) dosage, hemoglobin in
patients undergoing intravenous ascorbic acid treatment.
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non-responders group, weekly requirement of rhEPO was
slightly reduced at 3 months and 7 months, but there was
no signiﬁcant difference. In the control group, the weekly
requirement of rhEPO remained stable for 3 months of
treatment and 4 months afterward (Fig. 1B).
Effect of intravenous ascorbic acid on iron metabolism
In the IVAA responder group, serum iron and TSAT were
increased at 3 months and decreased at 7 months
(57722 mg/dL and 26711% at baseline, 108722 mg/dL
and 5277% at 3 months, and 61724 mg/dL and 30713%
at 7 months). Serum ferritin level was signiﬁcantly
decreased at 3 months (3777146 ng/mL at baseline vs.
2237145 ng/mL at 3 months, Po0.05, Fig. 2).
The serum iron, TSAT, TIBC, and serum ferritin of the
control group and IVAA non-responders group had no
signiﬁcant changes during these periods.
Correlation between serum vitamin C value and Hgb level,
rhEPO dose
The relationship between the level of serum vitamin
C and Hgb signiﬁcantly showed a positive correlation
(r¼0.405, Po0.05). Serum vitamin C values and rhEPO
dosage showed a negative correlation but no signiﬁcant
difference (P40.05, Fig. 3).Discussion
In this prospective, randomized, double-blind study, we
show that IVAA can be used as a potential adjuvant therapy
for HD patients with EPO-resistant normoferritinemic ane-
mia. Hgb was increased after IVAA administration, and
weekly requirement of rhEPO declined simultaneously at
3 months. We also found that the serum iron and TSATlevels (57 mg/dL and 26%, respectively, in this study) were
therapeutic markers as vitamin C administration in HD
patients with normoferritinemic anemia.
Anemia is a common complication that has remained
one of the most signiﬁcant and characteristic manifesta-
tions of CKD for more than 150 years [5,13]. The use of
bone marrow-stored iron has a critical role in CKD-
associated anemia in patients on dialysis [14]. Inadequate
iron storage and/or availability are the most common
causes of suboptimal response to rhEPO treatment in HD
Kidney Res Clin Pract 31 (2012) 48–5352patients [7,15]. Functional iron deﬁciency occurs when the
demand for iron exceeds the amount of tissue iron and
erythropoiesis accelerates after rhEPO treatment. Func-
tional iron deﬁciency is considered if TSAT and serum iron
levels are reduced, and serum ferritin levels were more
than 100 mg/L. The patients were unable to utilize high
levels of iron storage to improve their anemia [6,14].
Vitamin C represents one of the most prominent anti-
oxidants, exerting beneﬁcial effects by inhibition of lipid
peroxidation and by reducing endothelial dysfunction
[16]. Another possible mechanism for a better response
to EPO may be increased erythrocyte lifespan via both the
prevention of Hgb denaturation and erythrocyte mem-
brane lipid peroxidation [17]. It increases intestinal iron
absorption and induces iron mobilization from inert tissue
stores, including the reticuloendothelial system, and may
improve iron availability [18]. It also has a role Hgb
enzymatic incorporation of iron into protophorphyrin for
heme synthesis [19]. In addition, most intervention stu-
dies found an increase of TSAT and/or a decrease in ferritin
level in response to vitamin C [1,3,4]. Vitamin C deﬁciency
can interfere with iron absorption and utilization [5,12].
The effect of low vitamin C levels leads to a large amount
of iron to be stored, with relatively insufﬁcient utilization
for erythropoiesis. Improved vitamin C status may lead to
improvement of anemia in these patients [16]. Vitamin C
supplementation leads to a signiﬁcant increase in serum
iron, indicating that it aids mobilization of stored iron in
these patients. In this study, we found that the relation-
ship between the level of serum vitamin C and Hgb
signiﬁcantly showed a positive correlation.
Chronic HD patients generally have lower plasma
vitamin C levels. Vitamin C deﬁciency has complicated
the management of dialysis patients since the initiation of
renal replacement therapy, possibly caused by the loss of
vitamin C during dialysis, increased consumption, or
inadequate dietary intake [7,12]. Normal plasma vitamin
C levels in the nondialysis population are approximately
30–60 mmol/L. By contrast, plasma vitamin C in dialysis
patients is frequently o10 mmol/L, making the occur-
rence of scurvy a possible outcome. Vitamin C intake for
dialysis patients is often restricted because of the avoid-
ance of vitamin C-rich foods, and because of concerns
about oxalosis [12,16]. The vitamin C level of this study
group was 9.778.7 mmol/L.
Tarng et al. [20] found IVAA administration to be
effective in these cases. They studied HD patients with
serum ferritin more than 500 mg/L. All patients received
300 mg of vitamin C, three times a week intravenously for
8 weeks. Afterward, Hgb increased from 8.8 to 10.7 g/dL
and rhEPO dosage decreased to 2/3. Keven et al. [21]
studied HD patients without considering resistance to
rhEPO and iron level. The patients received 500 mg of
vitamin C intravenously (three times per week). At the
end, Hgb increased at least 1 g/dL. The studies indicate a
mechanism for the ability of high doses of vitamin C to
mobilize iron for erythropoiesis, as has been suggested by
several studies in rhEPO-resistant HD patients. Our work
in normoferritinemic anemia HD patients was conducted
after 3 months of ascorbic acid treatment. Patients withTSAT less than 25% had signiﬁcantly increased levels of
Hgb, hematocrit, TSAT, and signiﬁcantly decreased rhEPO
dose. In addition, Hgb and rhEPO dose did not change end
of study follow-up evaluation was conducted 4 months
after vitamin C treatment. However, serum ferritin levels
were signiﬁcantly decreased. These ﬁndings suggest that
IVAA treatment facilitates iron release from storage sites
and increases iron utilization in the erythropoiesis.
Our study has several limitations that should be con-
sidered. First, only a small number of patients were
enrolled in the study. Further large, prospective, placebo-
controlled studies are needed. Second, vitamin C treat-
ment might be a risk for the development of oxalosis in
HD patients. Although we did not evaluate oxalate levels,
Tarng et al. [17] showed no signiﬁcant increase in oxalate
levels in IVAA treatment.
In conclusion, our study conﬁrms that IVAA treatment
can improve normoferritinemic anemia and low TSAT in
HD patients. Further large-scale trials are needed.Conﬂict of interest
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